Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift - PubMed (original) (raw)
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift
Todd E Golde et al. Neuron. 2011.
Abstract
Most current Alzheimer's disease (AD) therapies in advanced phases of development target amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models suggest that anti-Aβ therapies may be highly effective if tested as agents to prevent or delay development of the disease or as therapies for asymptomatic patients with very early signs of AD pathology. However, anti-Aβ therapeutics are currently being tested in symptomatic patients where they are likely to be much less effective or ineffective. The lack of alignment between human clinical studies and preclinical studies, together with predictions about optimal trial design based on our understanding of the initiating role of Aβ aggregates in AD, has created a treatment versus prevention dilemma. In this perspective, we discuss why it is imperative to resolve this dilemma and suggest ways for moving forward in the hopes of enhancing the development of truly effective AD therapeutics.
© 2011 Elsevier Inc. All rights reserved.
Figures
Figure 1. Preclinical AD
The newly proposed staging of preclinical or prodromal AD reflects a cascade beginning with Aβ accumulation in the brain of clinically asymptomatic individuals and inexorably progressing to AD.
Similar articles
- Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA. Kocis P, et al. CNS Drugs. 2017 Jun;31(6):495-509. doi: 10.1007/s40263-017-0434-z. CNS Drugs. 2017. PMID: 28435985 Free PMC article. - The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Cooperative Study. Donohue MC, et al. JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803. JAMA Neurol. 2014. PMID: 24886908 Free PMC article. - Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ, Liu B, Frost JL, Lemere CA. Fu HJ, et al. CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017. CNS Neurol Disord Drug Targets. 2010. PMID: 20205640 Free PMC article. Review. - Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model.
Geerts H, Spiros A, Roberts P. Geerts H, et al. Alzheimers Res Ther. 2018 Feb 2;10(1):14. doi: 10.1186/s13195-018-0343-5. Alzheimers Res Ther. 2018. PMID: 29394903 Free PMC article. - Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R, Holtzman DM. Tarawneh R, et al. CNS Neurol Disord Drug Targets. 2009 Apr;8(2):144-59. doi: 10.2174/187152709787847324. CNS Neurol Disord Drug Targets. 2009. PMID: 19355934 Free PMC article. Review.
Cited by
- Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.
Lian Y, Jia YJ, Wong J, Zhou XF, Song W, Guo J, Masters CL, Wang YJ. Lian Y, et al. Mol Psychiatry. 2024 Feb;29(2):297-305. doi: 10.1038/s41380-023-02324-4. Epub 2023 Nov 24. Mol Psychiatry. 2024. PMID: 38001337 Review. - Intracerebral Nanoparticle Transport Facilitated by Alzheimer Pathology and Age.
Tracy GC, Huang KY, Hong YT, Ding S, Noblet HA, Lim KH, Kim EC, Chung HJ, Kong H. Tracy GC, et al. Nano Lett. 2023 Dec 13;23(23):10971-10982. doi: 10.1021/acs.nanolett.3c03222. Epub 2023 Nov 22. Nano Lett. 2023. PMID: 37991895 - The heritability of blood-based biomarkers related to risk of Alzheimer's disease in a population-based sample of early old-age men.
Gillespie NA, Elman JA, McKenzie RE, Tu XM, Xian H, Reynolds CA, Panizzon MS, Lyons MJ, Eglit GML, Neale MC, Rissman RA, Franz C, Kremen WS. Gillespie NA, et al. Alzheimers Dement. 2024 Jan;20(1):356-365. doi: 10.1002/alz.13407. Epub 2023 Aug 25. Alzheimers Dement. 2024. PMID: 37622539 Free PMC article. - DementiaBank: Theoretical Rationale, Protocol, and Illustrative Analyses.
Lanzi AM, Saylor AK, Fromm D, Liu H, MacWhinney B, Cohen ML. Lanzi AM, et al. Am J Speech Lang Pathol. 2023 Mar 9;32(2):426-438. doi: 10.1044/2022_AJSLP-22-00281. Epub 2023 Feb 15. Am J Speech Lang Pathol. 2023. PMID: 36791255 Free PMC article. - Experimental and real-world evidence supporting the computational repurposing of bumetanide for _APOE4_-related Alzheimer's disease.
Taubes A, Nova P, Zalocusky KA, Kosti I, Bicak M, Zilberter MY, Hao Y, Yoon SY, Oskotsky T, Pineda S, Chen B, Jones EAA, Choudhary K, Grone B, Balestra ME, Chaudhry F, Paranjpe I, De Freitas J, Koutsodendris N, Chen N, Wang C, Chang W, An A, Glicksberg BS, Sirota M, Huang Y. Taubes A, et al. Nat Aging. 2021 Oct;1(10):932-947. doi: 10.1038/s43587-021-00122-7. Epub 2021 Oct 11. Nat Aging. 2021. PMID: 36172600 Free PMC article.
References
- Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008;327:411–424. - PubMed
- ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800–1808. - PubMed
- Ashe KH. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem. 2001;8:301–308. - PubMed
- Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 2010;6:158–194. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG018454-10/AG/NIA NIH HHS/United States
- P01 AG020206-08/AG/NIA NIH HHS/United States
- R01 AG018454/AG/NIA NIH HHS/United States
- AG05142/AG/NIA NIH HHS/United States
- P01 AG020206/AG/NIA NIH HHS/United States
- AG020206/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical